Drug
LY2835219
LY2835219 is a pharmaceutical drug with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 4 completed trials
Completion Rate
100%(4/4)
Active Trials
1(20%)
Results Posted
100%(4 trials)
Phase Distribution
Ph phase_1
5
100%
Phase Distribution
5
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
5(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
4 of 4 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(1)
Completed(4)
Detailed Status
Completed4
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 15 (100.0%)
Trials by Status
active_not_recruiting120%
completed480%
Recent Activity
1 active trials
Showing 5 of 5
active_not_recruitingphase_1
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
NCT02057133
completedphase_1
A Study of LY2835219 in Japanese Participants With Advanced Cancer
NCT02014129
completedphase_1
A Study of LY2835219 in Healthy Participants
NCT02256267
completedphase_1
A Study of LY2835219 in Healthy Participants
NCT02059148
completedphase_1
A Study of LY2835219 in Healthy Participants
NCT02327143
Clinical Trials (5)
Showing 5 of 5 trials
NCT02057133Phase 1
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
NCT02014129Phase 1
A Study of LY2835219 in Japanese Participants With Advanced Cancer
NCT02256267Phase 1
A Study of LY2835219 in Healthy Participants
NCT02059148Phase 1
A Study of LY2835219 in Healthy Participants
NCT02327143Phase 1
A Study of LY2835219 in Healthy Participants
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5